Navigation Links
Cambrex Announces Significant New Supply Agreement
Date:8/14/2012

EAST RUTHERFORD, N.J., Aug. 14, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") announced that it has entered into an agreement to supply an active pharmaceutical ingredient for a customer's Phase 3 program during 2013 and 2014.  Under this non-exclusive supply arrangement, Cambrex will manufacture and deliver Phase 3 and pre-launch quantities of this product candidate. 

This agreement is expected to contribute over $20 million to 2013 revenues and potentially more in 2014 depending on regulatory developments, the timing of completion of Cambrex's capacity expansion related to this opportunity and meeting key product delivery milestones.  The agreement does not impact sales or profits in 2012 and does not include any commitments beyond 2014.  While there are certain protections built into the agreement related to early termination, the extent of this project's contribution to Cambrex is contingent upon our customer's Phase 3 program not being terminated or meaningfully reduced for any reason.

Shawn Cavanagh, Chief Operating Officer, said, "We are privileged to partner with this important new customer on such a significant project and are excited about successfully executing our capacity expansion so we can help our customer get this product candidate to market as quickly as possible.  Our customers routinely cite our excellent quality systems, regulatory record and experienced personnel as reasons for awarding us business, and each of these factors played a role in Cambrex being chosen for this project.  We continue to be excited about the pipeline of opportunities in front of us and are focused on making sure we have the resources in place to facilitate ongoing growth."

In order to meet the demand under the new agreement, Cambrex will invest significant capital over the remainder of 2012 and in early 2013 to expand our multipurpose large scale cGMP assets.  Consequently, the Company is re
'/>"/>

SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
2. Cambrex Reports First Quarter 2012 Results
3. Sunpeaks Ventures Announces Second Quarter 2012 Results
4. MultiCell Announces Results of Shareholders Meeting
5. ChemAxon Announces New Version of chemicalize.org for Tablet PCs
6. Naturs Design Announces the Dreams With Hope Tour, a Nationwide Sleep Awareness Campaign
7. ADVENTRX Announces Appointment Of Chief Medical Officer
8. FDAnews Announces Medical Device Mobile Apps Virtual Conference
9. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
10. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
11. WuXi PharmaTech Announces Second-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), the ... for a 2015 Connected World magazine Connected ... System (mPERS), that can be used anywhere, anytime. The ... In nominating MedScope, Landon Garner ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Denali Concrete Management Inc. (OTCBB: DCMG) announced today ... acquisition of Denali by Can-Fite BioPharma Ltd. (TASE: CFBI) ... outstanding shares of EyeFite Ltd., a private company incorporated ... exclusive license over CF101 for ophthalmic indications. Concurrently, Denali ...
... 22, 2011 Par Pharmaceutical Companies, Inc. (NYSE: ... approved the promotions of Thomas J. Haughey to the role ... Chief Operating Officer of the Company and its subsidiaries, effective ... LePore who will retain his title of Chairman of the ...
Cached Medicine Technology:Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer 2
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... , , , OAKLAND, Calif., ... host a Breema Intensive on February 6-14, 2010. The Intensive program ... to help advanced students deepen their practice of Breema and its ... Oakland, California. Participants can choose from a 2-day, 3-day or 6-day ...
... ... the more than 200 available models can be a daunting task. To ease the ... a series of eBooks on electric mobility scooters. Don’t get stuck in the mud ... ...
... ... rehab based in Texas, announced today that it has expanded its’ continuum of care with ... ... Origins Recovery, LLC announced today that it has expanded its’ continuum of care to include ...
... 28 The Providence Service Corporation (Nasdaq: PRSC ) ... last week by the United States Senate. The Senate ... Bill and therefore could still undergo substantial changes, has a ... many of the types of home and community based social ...
... have created what appears to be a schizophrenic mouse ... complex reasoning and decisions about appropriate social behavior. ... 28 in PNAS, elucidate the critical balance between excitation ... awry in schizophrenia. They also provide the first animal ...
... , NEW YORK, Dec. 28 The Michael J. ... $2 million to five research teams carrying out clinical studies ... in Parkinson,s disease, and help speed the development of urgently ... lead gift from The Edmond J. Safra Foundation, a steadfast ...
Cached Medicine News:Health News:The Breema Center Announces Its Winter Intensive 2Health News:The Breema Center Announces Its Winter Intensive 3Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 2Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 3Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 4Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 3Health News:Providence Service Corporation Comments on Senate Health Care Reform 2Health News:Providence Service Corporation Comments on Senate Health Care Reform 3Health News:Schizophrenia mouse model should improve understanding and treatment of the disorder 2Health News:Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinson's Disease 2Health News:Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinson's Disease 3
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... supplied on Smart Cards. Insert the card and ... and turns itself off after the programmed time. ... duration of treatments. Simply provide your patient with ... their progress on the next visit.,The initial set ...
... painfree therapy stimulates the spincter and ... contractions and relaxation. By use of ... surgical operations (bladder liftings) may be ... can improve unsatisfying results. DETRUSAM intravesical ...
... ELPHA 4 Conti is a battery operated ... treatment of conditions described below. ELPHA 4 Conti ... In STRESS- and faecal incontinence ELPHA 4 Conti ... that the user can feel which muscles need ...
Medicine Products: